BioLineRx is a commercial stage biopharmaceutical company with a development portfolio advancing motixafortide, a platform molecule targeting indications in stem cell mobilization (SCM) & in the treatment of advanced pancreatic cancer. The candidate is approved in the US for SCM and is undergoing studies for use in gene therapy and in pancreatic cancer. Gloria Biosciences has delayed the start of its motixafortide studies in Asia and the path forward is unclear. Ayrmid has assumed commercialization activities in the US. In September 2025, BioLineRx announced a JV with Hemispherian to develop GLIX1 in GBM. Phase I trials are expected to begin in 1Q:26. Motixafortide, a CXCR4 chemokine antagonist, mobilizes hematopoietic stem cells (HSCs) for transplantation in fewer apheresis sessions vs primary therapy, G-CSF. Many transplant-eligible patients have trouble achieving collection targets using SoC G-CSF alone & require additional agents to facilitate success. Motixafortide and G-CSF together achieved targeted collection in 88.3% of patients after only one apheresis session compared to 9.5% using G-CSF alone. FDA approval was granted in 2023 for SCM with further approvals expected overseas in the coming years. Commercialization is underway in the United States.
